Pharmacokinetic interaction of maraviroc with tacrolimus in a patient coinfected with HIV and hepatitis B virus following hepatic transplant due to hepatocellular carcinoma Sir, Limited data are available regarding interactions between tacrolimus and commonly used highly active antiretroviral therapies, such as first-line nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors (NNRTIs) and some protease inhibitors (PIs). When first-line combinations are contraindicated and newer antiretroviral agents are required, there are even less data on the interactions between newer agents such as maraviroc (a CCR5 inhibitor) with immunosuppressants such as tacrolimus (a calcineurin inhibitor). There are some animal model data of the beneficial effects on cardiac allograft survival when using maraviroc alongside immunosuppressants, with the potential that CCR5 inhibition could improve long-term outcomes after transplantation. 1, 2 In our patient undergoing hepatic transplant, with limited antiretroviral therapy options and the necessity to be started on a newer agent, we set out to observe concentrations of the immunosuppressant tacrolimus before and after administration of maraviroc to ensure that effective and non-toxic concentrations of both drugs were achieved.
We describe a 49-year-old man from Sierra Leone, recently diagnosed with fully sensitive HIV clade C and chronic hepatitis B virus (HBV). After routine blood tests revealed abnormal liver function tests (LFTs) and rising a-fetoprotein, ultrasound scan and then further imaging (CT and magnetic resonance imaging) demonstrated a focal 26 mm×20 mm hypodense lesion with a central nodular focus in the right lobe of the liver consistent with a hepatocellular carcinoma. Biopsy of the unaffected part of the liver revealed cirrhosis. Following a staging laparoscopy, the lesion was deemed not amenable to resection. The patient was put on the liver transplant waiting list and tenofovir/emtricitabine/efavirenz was started. He became undetectable for both HIV and HBV within 12 weeks, but suffered severe efavirenz-related CNS side effects. When called for liver transplantation 5 months later, he had an unplanned stop of his antiretrovirals. Post-transplant, in the intensive care unit, he went into acute renal failure, had grossly deranged LFTs and was also anaemic. He received hepatitis B immunoglobulin (10 000 units when the liver was removed, followed by 5000 units on days 1-3 post-transplant) with regular 12-weekly hepatitis B surface antibody checks to maintain concentrations .100 IU/mL. He was also established on the immunosuppressants tacrolimus (10 mg twice daily reduced to 2 mg twice daily), 500 mg of mycophenolate twice daily and 10 mg of prednisolone once daily. His CD4 count remained between 200 and 300 cells/mm 3 and the decision to restart antiretrovirals was made.
Tacrolimus is a substrate of cytochrome P450 3A4 (CYP3A4) and therefore concentrations can be dangerously elevated when co-administered with ritonavir-boosted PIs. This can cause fatal tacrolimus toxicity with a small dose of tacrolimus. Conversely, tacrolimus concentrations may be decreased with NNRTIs, and the concern regarding NNRTI resistance after his unplanned stop, previous severe side effects with efavirenz and continued mild derangement of LFTs precluded the use of efavirenz, nevirapine and etravirine. There are limited data on the use of maraviroc and raltegravir with these immunosuppressants, therefore possible interactions were predicted according to their metabolic pathways. Maraviroc and tacrolimus are both 0h30 01h00 02h00 03h00 04h00 06h00 12h00 t 1/2 AUC (h·ng/mL) substrates of CYP3A4, but neither inhibit or induce this isoenzyme. 3 The major mechanism of clearance of raltegravir is UGT 1A1-mediated glucuronidation and, since the active metabolite of mycophenolate, mycophenolic acid, is metabolized by glucuronyl transferase, there was caution regarding the use of raltegravir and mycophenolate.
After reviewing the limited data available, consideration of the metabolic pathways and an enhanced sensitivity trofile assay showing R5 tropism, tenofovir/emtricitabine and 300 mg of maraviroc twice daily were chosen. To ensure therapeutic and non-toxic concentrations of tacrolimus 4 and maraviroc were achieved, we observed tacrolimus concentrations (on 2 mg twice daily) without maraviroc and then subsequently after the addition of maraviroc. The patient then had blood drawn over 12 h at 0, 0 h 30 min, 1 h, 2 h, 3 h, 4 h, 6 h and 12 h. Trough tacrolimus concentrations were in keeping with recommended concentrations. After achieving steady state (2 weeks after commencing maraviroc), tacrolimus and maraviroc concentrations were taken at the same timepoints. Tacrolimus trough concentrations remained within the therapeutic range after co-administration of maraviroc and maraviroc concentrations were above the recommended trough concentration of 25 ng/mL 5 (see Figure 1 ). HIV virological suppression was achieved within 12 weeks (42 984 copies/mL to ,40 copies/mL), HBV DNA remained undetectable throughout and the patient remained negative for HBV surface antigen. The CD4 count rose to 483 cells/mm 3 with no side effects reported and no changes in laboratory parameters.
In conclusion, this clinical report provides the first clinical and pharmacological data to support the use of maraviroc in combination with tacrolimus in the setting of post-hepatic transplantation. Although there was a 21% increase in exposure to tacrolimus when in combination with maraviroc, both tacrolimus and maraviroc remained in the therapeutic range when co-administered. Unfortunately our patient had a hepatic artery thrombosis and is awaiting re-transplant, but there are emerging data of the potential use of maraviroc for prolonging graft survival. These initial observations need to be substantiated by formal pharmacokinetic interaction studies.
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